|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||93.05 / 128.39|
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences in November where Celgene management will provide an overview of the Company.
Wall Street enters the thick of earnings reporting in week three of the season with heavyweights Apple and Alphabet on tap.
Jim Cramer says he's not a fan of HOT, likes MAR or EXPE better.
M&A may dominate headlines, but investors need to watch earnings as well, says Jim Cramer.
Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.
This sector is one of the few areas of the market where you'll find myriad compelling values.
Celgene announced today that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral OTEZLA ® (apremilast) following a positive final appraisal determination from the National...
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.
Celgene's days of stellar growth will continue to stretch far into the future.
Celgene Corporation (NASDAQ: CELG) and Sage Bionetworks today announced a collaboration to develop an iPhone application utilizing the Apple ResearchKit framework to improve the understanding of the burden of disease for...
A close below $95 is likely to precipitate further short-term declines.
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that data from the open-label extension of the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with...
Investors had reduced expectations for Celgene's experimental pill for Crohn's disease, which makes the new clinical data released Sunday night look all right, although doubts will persist.
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the...
Celgene Corporation (NASDAQ:CELG) today announced that findings from clinical trials of investigational compounds GED-0301 (mongersen), ozanimod and RPC4046 will be presented at the United European Gastroenterology (UEG)...
Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced each company has entered into collaboration agreements with Abbott (NYSE: ABT), a leader in diagnostic technologies, to develop...
Don't focus on just one day of trading, Jim Cramer says.
On days like this, the money just keeps sloshing around.
The FDA's pattern could be trouble for Dynavax' vaccine.
Celgene Corporation (NASDAQ:CELG) today announced that the data from a randomized, double-blind, multicenter, exploratory phase Ib study evaluating the effects of oral GED-0301 (mongersen) on both endoscopic and clinical...
Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, October 27, 2016 at 9 a.
Doug Kass shares his thoughts on the banks and looks back on 20 years with TheStreet.
BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.
Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.
Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...
The market is fearful. Use that fear to buy, Cramer says.
Hedge fund billionaire Dan Loeb owns a greater than 17% stake in the newly public developer of a drugs including those for treatment of psoriasis.